Anlon Healthcare (NSE:AHCL) Current Deferred Revenue: ₹0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

NSE:AHCL Anlon Healthcare Ltd NSE:AHCL
20 GF Score
Price ₹14.49
! 4 Warning Signs
View Full Analysis

What is Anlon Healthcare Current Deferred Revenue?

Anlon Healthcare NSE:AHCL -0.55% 20 Current Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus rates NSE:AHCL with a GF Score™ of 20/100. The stock has 4 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Anlon Healthcare's current deferred revenue for the quarter that ended in Jun. 2026 was ₹0 Mil.

Anlon Healthcare Current Deferred Revenue Related Terms

Anlon Healthcare Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Anlon Healthcare's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anlon Healthcare Current Deferred Revenue Chart

Anlon Healthcare Annual Data
Trend Mar22 Mar23 Mar24 Mar25 Mar26
Current Deferred Revenue
0.00 0.00 0.00 0.00 0.00

Anlon Healthcare Quarterly Data
Mar22 Mar23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
NSE:AHCL
20GF Score
Anlon Healthcare Ltd NSE:AHCL
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of ₹0 Mil mean?
Anlon Healthcare (NSE:AHCL) has a Current Deferred Revenue of ₹0 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Anlon Healthcare and its competitors.
Is Anlon Healthcare's Current Deferred Revenue too high?
Anlon Healthcare's current Current Deferred Revenue is ₹0 Mil. Overall, Anlon Healthcare has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's Current Deferred Revenue compare to ZTS?
Anlon Healthcare's Current Deferred Revenue of ₹0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Drug Manufacturers company?
A good Current Deferred Revenue depends on the Drug Manufacturers industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Anlon Healthcare and its competitors. Anlon Healthcare's current Current Deferred Revenue is ₹0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current Current Deferred Revenue of ₹0 Mil. The current Current Deferred Revenue is ₹0 Mil. Anlon Healthcare's overall GF Score™ is 20/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current Current Deferred Revenue is ₹0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anlon Healthcare Business Description

Other Exchanges 544497:India
Address Kalawad Road, 101/102, Silvercoin Complex, Opposite Crystal Mall, Rajkot, GJ, IND, 360 005
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
20GF Score

Get the complete analysis for NSE:AHCL

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹14.49
Price